HLA-Specific Primer Panel for Microchimerism Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack sensitivity and effectiveness in quantitatively identifying and monitoring allogeneic cells, tissues, and nucleic acids associated with autoimmune diseases, malignancies, transplant rejection, and pregnancy-related pathologies, particularly in detecting microchimerism and its implications.
Innovation Solution
Compositions and methods involving specific forward, reverse, and probe nucleic acid molecules with fluorophores and quenchers, targeting HLA alleles and genetic polymorphisms, are used for quantitative PCR to detect and quantify microchimerism, monitor allograft rejection, and assess anti-malignancy effects, employing a panel of nucleic acid molecules specific for various HLA alleles and polymorphisms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional methods are used to detect allogeneic cells and nucleic acids, then the detection process is simple, but the sensitivity and effectiveness are insufficient
Solution Approach 1:
The detection system is segmented into multiple specialized components: HLA-specific primer pairs targeting individual alleles, allele-specific probes with fluorophores and quenchers, and a quantitative PCR apparatus. This segmentation allows each component to be optimized for specific detection tasks, achieving high sensitivity while maintaining manageable complexity through modular design.
Solution Approach 2:
The method utilizes parameter changes in the PCR process, including temperature cycling, fluorophore excitation wavelengths, and threshold setting, to enhance detection sensitivity. By optimizing these parameters for each HLA allele pair, the system achieves precise quantification of allogeneic nucleic acids in complex biological samples.
2Adaptability or versatility
If a panel of HLA-specific nucleic acid molecules is used to detect multiple alleles, then the detection coverage is improved, but the complexity of the system increases
Solution Approach 1:
The quantitative PCR platform is designed with universal applicability through a standardized protocol that can detect multiple HLA alleles simultaneously. The same basic PCR machinery and analysis pipeline work for all HLA-A, HLA-B, HLA-C, and HLA-DRB1 alleles, reducing operational complexity while maintaining broad detection coverage through the comprehensive allele-specific primer and probe panel.
3Measurement precision
If quantitative PCR is used to detect rare nucleic acid molecules, then the detection sensitivity is improved, but the difficulty of detecting and measuring increases
Solution Approach 1:
Allele-specific probes serving as intermediaries between the target HLA nucleic acids and the detection system enable sensitive quantification. These probes, containing fluorophores and quenchers, bind specifically to each HLA allele sequence, converting the presence of rare allogeneic molecules into measurable fluorescence signals that can be accurately quantified even in the presence of overwhelming host DNA.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach enables sensitive detection of rare nucleic acid molecules, effectively monitoring microchimerism, allograft rejection, and malignancy, providing non-invasive tools for early detection and management of related conditions.
Implementation Method 1
a probe nucleic acid molecule comprising a fluorophore and a quencher
Data Source
AI summary
The present disclosure provides a panel of nucleic acid molecule primers specific for HLA-specific alleles and other genetic polymorphisms, which are useful for quantitatively amplifying these markers to detect, diagnose, and monitor individuals who have or are at risk of certain disease conditions, such as autoimmune disease, proliferative disease, infectious disease, allograft rejection, or pregnancy-related pathologies.